Black Diamond Therapeutics (BDTX) Asset Utilization Ratio (2025)

Black Diamond Therapeutics (BDTX) posted Asset Utilization Ratio of 0.47 for Q4 2025, up 7.77% on a QoQ basis from 0.43 in Q3 2025.

Black Diamond Therapeutics (BDTX) Asset Utilization Ratio (2025) Analysis & Trends

Black Diamond Therapeutics' Asset Utilization Ratio history runs 1 years deep, the most recent figure standing at 0.47 for Q4 2025.

Quarterly Asset Utilization Ratio changed N/A year-over-year to 0.47 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.47 (changed N/A YoY) and the FY2025 annual result came in at 0.53, changed N/A from the prior year.
Asset Utilization Ratio was 0.47 for Q4 2025 at Black Diamond Therapeutics, up from 0.43 in the prior quarter.
Across five years, Asset Utilization Ratio topped out at 0.47 in Q1 2025 and bottomed at 0.41 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	0.69
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	0.47
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	0.37
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	-
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	Black Diamond Therapeutics	99.59 Mn	-18.67 Mn	-	-

Download Data